pranolol(1 mg/kg,as iv bolus at -6O');B)GRF(l mcg/kg,as iv bolus at O');C)Propranolol(as in A)+GRF(as in B height velocity and partial GH deficiency in response to two pharmacological tests (maxlmum peak 11 ng/ml) received GRF for 6 months (10 mcg/kg/day) as a subcutaneous injection (8 p.m.). 24-hours GH secretion was studied before and after 3 months of treatment : SmC dosage and a IV GRF test ( 2 mcg/kg) was done before and after 6 months of treatment. Lower leg length was studied every 3 weeks by knemometry and statural growth at 3 months intervals.
Height velocity increased in 5 cases from 2.5 2 0.5 to 4.4 + 1.1 cm for the 6 months period and showed no change in 2 cases. Knemometric growth rate is subject to wlde variations and 1s difficult to take into account. There was no sign of desens~tization: 24-hour secretion (mx peak and I.C.) was higher after 3 months treatment (m = 16.2 + 7.5 ng/ml and 3.7 ' 1.2 ng/ml/min before, 29 + 17.9 ng/ml and 4.5 + 2.9 ng/ml/min afterwsrds), as was the GH peak in the IV GRF test after 6 m,onths treatment (m = 36.1 ng/ml before, 47.8 ng/ml afterwards). SmC level was hlgher on average after 6 months treatment (1.9 + 1 U/ml and 0.8 + 0.5 U/ml before treatment). The analysis of the various parameters (GH secretion, SmC) provided no elements to account for the lack of therapeutic response in the 2 cases. These results suggest that GRF treatment may be considered as a therapeutic alternative in GH deficiencies. lk bicchmical and p m t h mpnses t~ GUH(1-2'3)NH2 therapy were studied in 18 preplbertal 814eficient children (14 idiopathic, 3 cranial irradiation, 1 sepb-optic dysplasia; 16 rrale, 2 fenlale, man age 9.5 years, tms 6.8 -14.2 years). 81 deficiency was defined as a peak 81 to stindation of less than 7 niU/l. Farrteen children had received K T I treablent which was stopped at least 3 mnths before t k trial. M 1 was given as mice daily sc irijections i n individml cbses of 250 pg (children less tbn 2U ly bw), and 500 pg (gmter than 20 I & . Peak sem 81 respnse to WRi before t m b e n t was 25.8 + 6.3 mU/1
(mean + SE) and after 3 mnths 27.4 + 4.2 nU/l; indicating m desemitisation effect. Thirteen of the 18 s M an i n c m t in h e w t velccity after 3 mnths therapy, in 6 this was p t e r than 2 an/year and in 3 gmter than 5 adyear.
Trim children s W a grater height velccity on CXRi tbn on KiH. U b t children have mpleted 6 m n t k therapy and 3 have shwn an i n c m n t in height velccity of 0.4, 2.5, and 3.1 an/year. lkre was r n amlation bethen t k p x t h resprm at 3 m n t b and pre-treatment 81 respnse to CWM. In oonclusicn, we bave shwn U?at twice daily sc Q W ! therapy is a safe treaixent which praroted linear p m t h at 3 m m t b i n 13 of 1 8 CE-deficient children. W e r , predictors of gcd p3owth mpnses could m t be identified. 5 children (8.24+/-3.63 years) with growth retardation (3.4 +/-0.9 DS)bone age retardation (3.13+/-2.40 years) and insufficient growth velocity (3.9+/-0.6 cmlyear) related with complete (n=2) or partial (n=3) GH deficiency were treated with a daily dose of 300 mcg GRF administred subcutaneously (SC)every other week for a 6 months period. GH response to SC CRF administration, GH and GRF antibodies and somatomedins were studied on repeated blood samples performed on day I and day 8 of the first week of treatment as well as at the end of the 6 months therapy. Growth velocity increased to 6.16+/-1.17 cmlyear. 3 of the 5 patients have accelerated growth mainly for the first 3 months. Linear growth was increased in complete (+2.5 and 4.3 cm/year) more than in partial (+0.4, +0.8 and +3.3 cm/year) GH deficient children. The area under the GH curve after GRF administration was 1050.7+/-767.7 on day 1, 472.1+/-103.2 on day 8 and 631.9 +I-148.1 ng/ml x min. after 6 months therapy. No major change in other hormonal evaluations was noted. These results confirm that GRF can stimulate linear growth in some GH deficient children and lead to discuss the role of limiting factors in its long term effects such as desensitization, antibodies or somatostatin. 
PULSATILE GROWTH HORMONE RELEASING HORMONE TREATMENT OF GH DEFICIENCY
We have treated 1 1 prepubertal children (7M;4F) with idiopathic GH deficiency due to pituitary hypoplasia using GHRH 1-40. This was administered subcutaneously for 4 pulses at 3 hourly intervals at night in a dose of 1-2pglkglpulse. Blood samples for GH concentrations were taken at 20 minute intervals for 24 hours before treatment and throughout the study monthly at night.
Pulsatile GH secretion was induced in 10 children from the first night of treatment and the response augmented with time. Growth velocity in 8 of 1 1 children increased from 3.3cmjyr (range 1.7 to 4.9) before treatment to 6.9cmIyr (range 5-8.5) on GHRH. 2 children had no change in height velocity and one had a progressive diminution of CH secretion and a fall in growth velocity.
GHRH (lvg/kg) was also administered intravenously to all children before treatment and at 3 monthly intervals. Although a GH response was seen on all occasions, the responses predicted neither the GH concentrations nor the growth velocities obtained on long term s.c. treatment.
Pulsatile administration of CHRH 1-40 was effective in inducing GH secretion and promoting growth acceleration in the majority of children with idiopathic GH deficiency. Res. 18, 107 (1984) 
